Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

Phase III trial of Maraviroc combo fails to meet endpoint for HIV-ViiV HealthCare

23-Jul-2014

The 48-week results from the Phase ...

Avastin is filed at FDA for treatment of Ovarian Cancer- Genentech/Roche

23-Jul-2014

Genentech announced that the FDA has ...

FDA committees meet to investigate Testosterone Deficiency therapy

23-Jul-2014

On 17 September the FDA's Bone, ...

FDA grants section 510(k) clearance to Calypso soft tissue Beacon transponder-Varian Medical

22-Jul-2014

Varian Medical Systems announced ...

FDA approves Rebel Platinum Chromium Coronary Stent System-Boston Scientific

22-Jul-2014

Boston Scientific Corporation has ...

Phase III trial data for Eylea in Diabetic Macular Oedema-Regeneron Pharma

20-Jul-2014

In the Phase III VIVID-DME trial of ...

Ruconest approved by FDA for treatment of Hereditary Angioedema- Salix Pharma

19-Jul-2014

Salix Pharmaceuticals, Ltd. and ...

Recent Updates

Drugs

Clinical Guidelines

Atopic eczema in children

2013 ESH/ESC Guidelines for the management of arterial hypertension

Heavy menstrual bleeding

Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

Medical Journals

Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry

Hepatic cytokine response can be modulated using the Kupffer cell blocker gadolinium chloride in obstructive jaundice

How to manage vaccinations in children with cancer

Embelin inhibits growth and induces apoptosis through the suppression of Akt/mTOR/S6K1 signaling cascades

epgonline.org Social